CN106349347B - 一种小分子多肽、及其编码基因和应用 - Google Patents
一种小分子多肽、及其编码基因和应用 Download PDFInfo
- Publication number
- CN106349347B CN106349347B CN201610938432.6A CN201610938432A CN106349347B CN 106349347 B CN106349347 B CN 106349347B CN 201610938432 A CN201610938432 A CN 201610938432A CN 106349347 B CN106349347 B CN 106349347B
- Authority
- CN
- China
- Prior art keywords
- cell
- socs1
- micromolecule polypeptide
- inflammatory diseases
- chronic inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 74
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 67
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 67
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 24
- 230000006907 apoptotic process Effects 0.000 claims abstract description 41
- 101150045565 Socs1 gene Proteins 0.000 claims abstract description 38
- 102000058018 Suppressor of Cytokine Signaling 1 Human genes 0.000 claims abstract description 38
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims abstract description 38
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 18
- 210000001842 enterocyte Anatomy 0.000 claims abstract description 18
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000011231 Crohn disease Diseases 0.000 claims description 13
- 230000026731 phosphorylation Effects 0.000 claims description 9
- 238000006366 phosphorylation reaction Methods 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 76
- 150000001413 amino acids Chemical group 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 9
- 230000001594 aberrant effect Effects 0.000 abstract description 8
- 230000003993 interaction Effects 0.000 abstract description 7
- 230000010250 cytokine signaling pathway Effects 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 abstract description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 238000000034 method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 14
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000012549 training Methods 0.000 description 7
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000005336 cracking Methods 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010087924 alanylproline Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108010090894 prolylleucine Proteins 0.000 description 4
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PKOHVHWNGUHYRE-ZFWWWQNUSA-N (2s)-1-[2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)NCC(=O)N1CCC[C@H]1C(O)=O PKOHVHWNGUHYRE-ZFWWWQNUSA-N 0.000 description 2
- PCDUALPXEOKZPE-DXCABUDRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O PCDUALPXEOKZPE-DXCABUDRSA-N 0.000 description 2
- VBRDBGCROKWTPV-XHNCKOQMSA-N Ala-Glu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N VBRDBGCROKWTPV-XHNCKOQMSA-N 0.000 description 2
- WGDNWOMKBUXFHR-BQBZGAKWSA-N Ala-Gly-Arg Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N WGDNWOMKBUXFHR-BQBZGAKWSA-N 0.000 description 2
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 2
- GNYUVVJYGJFKHN-RVMXOQNASA-N Arg-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N GNYUVVJYGJFKHN-RVMXOQNASA-N 0.000 description 2
- IGFJVXOATGZTHD-UHFFFAOYSA-N Arg-Phe-His Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccccc1)C(=O)NC(Cc2c[nH]cn2)C(=O)O IGFJVXOATGZTHD-UHFFFAOYSA-N 0.000 description 2
- FTNVLGCFIJEMQT-CIUDSAMLSA-N Asp-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N FTNVLGCFIJEMQT-CIUDSAMLSA-N 0.000 description 2
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 2
- XAPPCWUWHNWCPQ-PBCZWWQYSA-N Asp-Thr-His Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O XAPPCWUWHNWCPQ-PBCZWWQYSA-N 0.000 description 2
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 2
- KZTLOHBDLMIFSH-XVYDVKMFSA-N His-Ala-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O KZTLOHBDLMIFSH-XVYDVKMFSA-N 0.000 description 2
- IMCHNUANCIGUKS-SRVKXCTJSA-N His-Glu-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IMCHNUANCIGUKS-SRVKXCTJSA-N 0.000 description 2
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 2
- FBCURAVMSXNOLP-JYJNAYRXSA-N His-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N FBCURAVMSXNOLP-JYJNAYRXSA-N 0.000 description 2
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 2
- NFHJQETXTSDZSI-DCAQKATOSA-N Leu-Cys-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NFHJQETXTSDZSI-DCAQKATOSA-N 0.000 description 2
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 2
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 2
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- BBDSZDHUCPSYAC-QEJZJMRPSA-N Phe-Ala-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BBDSZDHUCPSYAC-QEJZJMRPSA-N 0.000 description 2
- JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 2
- ZWJKVFAYPLPCQB-UNQGMJICSA-N Phe-Arg-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O ZWJKVFAYPLPCQB-UNQGMJICSA-N 0.000 description 2
- RJYBHZVWJPUSLB-QEWYBTABSA-N Phe-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N RJYBHZVWJPUSLB-QEWYBTABSA-N 0.000 description 2
- VADLTGVIOIOKGM-BZSNNMDCSA-N Phe-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CN=CN1 VADLTGVIOIOKGM-BZSNNMDCSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 2
- VXCHGLYSIOOZIS-GUBZILKMSA-N Pro-Ala-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 VXCHGLYSIOOZIS-GUBZILKMSA-N 0.000 description 2
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 2
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 2
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 2
- QWZIOCFPXMAXET-CIUDSAMLSA-N Ser-Arg-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O QWZIOCFPXMAXET-CIUDSAMLSA-N 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- NMANTMWGQZASQN-QXEWZRGKSA-N Val-Arg-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N NMANTMWGQZASQN-QXEWZRGKSA-N 0.000 description 2
- CVUDMNSZAIZFAE-UHFFFAOYSA-N Val-Arg-Pro Natural products NC(N)=NCCCC(NC(=O)C(N)C(C)C)C(=O)N1CCCC1C(O)=O CVUDMNSZAIZFAE-UHFFFAOYSA-N 0.000 description 2
- XBJKAZATRJBDCU-GUBZILKMSA-N Val-Pro-Ala Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O XBJKAZATRJBDCU-GUBZILKMSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- 108010070944 alanylhistidine Proteins 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 108010092114 histidylphenylalanine Proteins 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 108010064486 phenylalanyl-leucyl-valine Proteins 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011506 response to oxidative stress Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- HJWQFFYRVFEWRM-SRVKXCTJSA-N Arg-Arg-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O HJWQFFYRVFEWRM-SRVKXCTJSA-N 0.000 description 1
- RWWPBOUMKFBHAL-FXQIFTODSA-N Arg-Asn-Cys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O RWWPBOUMKFBHAL-FXQIFTODSA-N 0.000 description 1
- GIVWETPOBCRTND-DCAQKATOSA-N Arg-Gln-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GIVWETPOBCRTND-DCAQKATOSA-N 0.000 description 1
- UFBURHXMKFQVLM-CIUDSAMLSA-N Arg-Glu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UFBURHXMKFQVLM-CIUDSAMLSA-N 0.000 description 1
- LLUGJARLJCGLAR-CYDGBPFRSA-N Arg-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LLUGJARLJCGLAR-CYDGBPFRSA-N 0.000 description 1
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- FJIRXKVEDFLLOQ-SRVKXCTJSA-N Asn-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N FJIRXKVEDFLLOQ-SRVKXCTJSA-N 0.000 description 1
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 1
- VHQSGALUSWIYOD-QXEWZRGKSA-N Asn-Pro-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O VHQSGALUSWIYOD-QXEWZRGKSA-N 0.000 description 1
- NWAHPBGBDIFUFD-KKUMJFAQSA-N Asp-Tyr-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O NWAHPBGBDIFUFD-KKUMJFAQSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010039499 Cartilage sarcomas Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- KWUSGAIFNHQCBY-DCAQKATOSA-N Gln-Arg-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O KWUSGAIFNHQCBY-DCAQKATOSA-N 0.000 description 1
- MWLYSLMKFXWZPW-ZPFDUUQYSA-N Gln-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O MWLYSLMKFXWZPW-ZPFDUUQYSA-N 0.000 description 1
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 1
- ZMVCLTGPGWJAEE-JYJNAYRXSA-N Glu-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)O)N)O ZMVCLTGPGWJAEE-JYJNAYRXSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- BXSZPACYCMNKLS-AVGNSLFASA-N Glu-Ser-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O BXSZPACYCMNKLS-AVGNSLFASA-N 0.000 description 1
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 1
- QAMMIGULQSIRCD-IRXDYDNUSA-N Gly-Phe-Tyr Chemical compound C([C@H](NC(=O)C[NH3+])C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C([O-])=O)C1=CC=CC=C1 QAMMIGULQSIRCD-IRXDYDNUSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- AZEYWPUCOYXFOE-CYDGBPFRSA-N Ile-Arg-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)O)N AZEYWPUCOYXFOE-CYDGBPFRSA-N 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- JUWJEAPUNARGCF-DCAQKATOSA-N Leu-Arg-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JUWJEAPUNARGCF-DCAQKATOSA-N 0.000 description 1
- REPPKAMYTOJTFC-DCAQKATOSA-N Leu-Arg-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O REPPKAMYTOJTFC-DCAQKATOSA-N 0.000 description 1
- WGNOPSQMIQERPK-GARJFASQSA-N Leu-Asn-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N WGNOPSQMIQERPK-GARJFASQSA-N 0.000 description 1
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- IWTBYNQNAPECCS-AVGNSLFASA-N Leu-Glu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IWTBYNQNAPECCS-AVGNSLFASA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- HZVXPUHLTZRQEL-UWVGGRQHSA-N Met-Leu-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O HZVXPUHLTZRQEL-UWVGGRQHSA-N 0.000 description 1
- 101000964435 Mus musculus Z-DNA-binding protein 1 Proteins 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- YXHYJEPDKSYPSQ-AVGNSLFASA-N Pro-Leu-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 YXHYJEPDKSYPSQ-AVGNSLFASA-N 0.000 description 1
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- YIUWWXVTYLANCJ-NAKRPEOUSA-N Ser-Ile-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O YIUWWXVTYLANCJ-NAKRPEOUSA-N 0.000 description 1
- RWDVVSKYZBNDCO-MELADBBJSA-N Ser-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)N)C(=O)O RWDVVSKYZBNDCO-MELADBBJSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- NSGZILIDHCIZAM-KKUMJFAQSA-N Tyr-Leu-Ser Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NSGZILIDHCIZAM-KKUMJFAQSA-N 0.000 description 1
- RGJZPXFZIUUQDN-BPNCWPANSA-N Tyr-Val-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O RGJZPXFZIUUQDN-BPNCWPANSA-N 0.000 description 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
- CVUDMNSZAIZFAE-TUAOUCFPSA-N Val-Arg-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N CVUDMNSZAIZFAE-TUAOUCFPSA-N 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- -1 hydroxymethyl phenoxy methyl Chemical group 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108010025826 prolyl-leucyl-arginine Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及生物医药技术领域，具体涉及一种小分子多肽、及其编码基因和在制备治疗慢性炎症疾病药物中的应用。小分子多肽，具有如SEQ ID No.1所示的氨基酸序列。本发明基于非受体酪氨酸激酶(Fyn)与细胞因子信号通道抑制剂‑1(SOCS1)的相互作用结构域的确立，构建出了多肽(SS2)，并通过细胞生物学实验证明本发明的小分子多肽(SS2)具有抑制肠上皮细胞异常凋亡的作用。
Description
技术领域
本发明涉及生物医药技术领域，具体涉及一种小分子多肽及其编码基因，以及该小分子多肽在制备治疗慢性炎症疾病(抑制肠上皮细胞异常凋亡)药物中的应用。
背景技术
克罗恩(Crohn’s diseases CD)是一种胃肠道慢性炎性肉芽肿性疾病。近年来，CD发病率逐年增加，且有终生复发倾向，重症患者迁延不愈，预后不良，严重影响患者的生活质量。长久以来克罗恩病的治疗是临床上的难点之一，本病尚无特殊治疗方法。无并发症时，支持疗法和对症治疗十分重要，可缓解有关症状。常用药物有水杨酸类和肾上腺皮质激素，其中柳氮磺胺吡啶和5-氨基水杨酸(5-ASA)适用于慢性期和轻、中度活动期病人，肾上腺皮质激素常用于中、重症或暴发型患者，许多病人出现并发症，需手术治疗，手术治疗用于完全性肠梗阻、肠瘘与脓肿形成、急性穿孔或不能控制的大出血，以及难以排除癌肿的患者。以上治疗方法中药物治疗用于抑制炎症活动，控制炎症缓解症状，改善全身状况，但是近年来大量临床观察发现5-ASA药物对缓解期维持疗效不肯定，抗生素因长期使用出现胃肠道副作用，糖皮质激素可以使患者免疫功能下降，对人体造成一系列毒副作用。而手术治疗的术后复发率很高。因此寻找新的克罗恩病的治疗手段十分重要。
基于CD的发生发展及治疗预后的机制研究中，普遍认为在遗传易感的基础上，各种内外源性诱因的作用下肠道免疫系统发生异常，导致肠道的屏障结构破坏，最终导致疾病的发生。完整的肠黏膜上皮细胞组成重要的肠道屏障抵御外界毒素和抗原物质入侵，选择性允许营养物质、电解质和水的吸收，维持机体内环境稳态，所以肠上皮细胞异常凋亡是肠黏膜机械屏障破坏的主要发生机制。因此控制肠上皮细胞异常凋亡成为减轻炎症诱导上皮屏障破坏的关键环节。
在炎症诱导肠道上皮细胞异常凋亡的同时，肠上皮细胞炎症环境下由细胞因子激活产生细胞因子信号通道抑制剂-1(SOCS1)表达增高，非磷酸化SOCS1抑制JAK1/STAT1信号通道，从而抑制下游靶caspase3,9的表达是抑制细胞凋亡修复肠道上皮抑制疾病进展的关键。但在CD发展过程中SOCS1被磷酸化，磷酸化的SOCS1失去抑制JAK1/STAT1信号通道作用，同时抑制凋亡能力受损，肠上皮细胞持续凋亡。近期研究表明，在炎症环境中还会发生严重的氧化应激反应，氧化应激诱导产生Fyn,CD发展过程中FYN表达增高，与肠上皮细胞凋亡密切相关，FYN属蛋白酪氨酸激酶家族(SRC家族)，通过调节多种细胞信号通道参与调节细胞凋亡等过程，主要通过磷酸化下游靶基因发挥作用。
关于细胞因子信号通道抑制剂-1(SOCS1)由IL-1beta诱导抑制软骨代谢方面的相关报道，可参考文献(1、Arthritis Res Ther.2013；15(6):R191.Cytokine signaling-1suppressor is inducible by IL-1beta and inhibits the catabolic effects ofIL-1beta in chondrocytes:its implication in the paradoxical joint-protectiverole of IL-1beta.；2、Choi YS,Park JK,Kang EH,Lee YK,Kim TK,Chung JH,ZimmererJM,Carson WE,Song YW,Lee YJ.)。
发明内容
本发明的目的在于提供一种小分子多肽及其编码基因，以及该小分子多肽在制备治疗慢性炎症疾病药物中的应用。
本发明基于非受体酪氨酸激酶(Fyn)与细胞因子信号通道抑制剂-1(SOCS1)的相互作用结构域的确立，构建出了多肽(SS2)，并通过细胞生物学实验证明本发明的小分子多肽(SS2)具有抑制肠上皮细胞异常凋亡的作用。
本发明的目的主要通过以下技术方案实现：
本发明的第一目的在于提供一种小分子多肽，具有如SEQ ID No：1所示的氨基酸序列。
本发明的第二目的在于提供编码上述小分子多肽的基因，具有如SEQ ID No.2所示的核苷酸序列。
本发明的第三目的在于提供小分子多肽在制备治疗慢性炎症疾病药物中的应用。
进一步的，所述的慢性炎症疾病为克罗恩病、骨关节炎、肺炎、肝炎等。
进一步的，所述的慢性炎症疾病是指肠上皮细胞在炎症环境下，由细胞因子激活产生的SOCS1被氧化应激诱导产生Fyn磷酸化，使SOCS1失去抑制细胞凋亡能力的疾病。
进一步的，本发明还提供该小分子多肽及其编码基因在制备抑制肠上皮细胞异常凋亡药物中的应用。
本发明的再一目的在于提供一种药物组合物，其包含上述小分子多肽以及药学上可接受的载体。
进一步的，所述药学上可接受的载体为药学上可接受的赋形剂，悬浮剂，填充剂和/或稀释剂。
本发明是基于CD发展中肠上皮细胞凋亡机制和治疗难点，通过抗凋亡基因治疗途径发明一段重组多肽，证明其具有抗凋亡的应用价值，并提供一段抗凋亡肽的特异的氨基酸序列和核苷酸序列。
本发明的小分子多肽抑制肠上皮细胞异常凋亡的具体机理是：在肠上皮细胞炎症环境下由细胞因子激活产生的SOCS1本身具有抑制细胞因子信号通道的作用从而抑制JAK1/STAT1信号通道，抑制下游靶基因Caspase-3等分子表达从而抑制细胞凋亡，但是在炎症环境中还会发生严重的氧化应激反应，氧化应激诱导产生Fyn,分子Fyn磷酸化SOCS使其失去抑制细胞凋亡能力，研究发现Fyn与SOCS1发生作用的主要区域即为SS2区域，SS2过表达的细胞或组织内，SS2可以和Fyn发生竞争性的结合，抑制SOCS1与Fyn的结合，抑制SOCS1的磷酸化，恢复和维持SOCS1的抑制炎症反应和细胞凋亡的作用。
本发明利用生物工程技术，基因重组一段71个氨基酸(amino acid)多肽对应的DNA序列到GFP真核表达载体。经酶切和序列分析证明重组成功后，将此真核表达重组多肽转染到肠上皮细胞，免疫印迹证明多肽的蛋白表达，实现了多肽的重组。接着对多肽的抗凋亡功能进行了研究，细胞学和小鼠体内实验表明此多肽具有抑制肠上皮细胞凋亡和缓解小鼠克罗恩病的发生发展的功能。
本发明发现CD发生部位FYN表达增高并且与SOCS1存在相互作用，分子Fyn磷酸化SOCS使其失去抑制细胞凋亡能力，研究发现Fyn与SOCS1发生作用的主要区域即为SS2区域，SS2抑制肠上皮细胞异常凋亡的具体机理是：SS2过表达的细胞或组织内，SS2可以和Fyn发生竞争性的结合，抑制SOCS1与Fyn的结合，抑制SOCS1的磷酸化，恢复和维持SOCS1的抑制炎症反应和细胞凋亡的作用。该多肽的设计为CD等慢性炎症疾病发生过程中缓解抑制炎症因子介导的肠上皮细胞凋亡提供新的药物设计和治疗靶点。
附图说明
图1为疾病活动指数(DAI)的检测；
图2为大体观察及评分；
图3为组织学评分；
图4为Western Blot检测SOCS1和FYN表达；其中，A为组织中两分子相互作用，B为细胞中两分子相互组作用；
图5为Western Blot检测SOCS1的SS2结构域和FYN之间的相互作用；
图6为小分子多肽在细胞模型中的流式细胞术检测HT-29及凋亡情况；其中，a表示没有处理的细胞；b表示单独使用H2O2处理的细胞；c表示H2O2+SOCS1S1处理的细胞；d表示H2O2+SS2处理的细胞；e表示H2O2+SOCS1S3；f表示统计学；
图7为小分子多肽在细胞模型中的FACS检测细胞周期；其中，其中，a表示没有处理的细胞；b表示单独使用H2O2处理的细胞；c表示H2O2+SOCS1S1处理的细胞；d表示H2O2+SS2处理的细胞；e表示H2O2+SOCS1S3；f表示统计学；
图8为小分子多肽在细胞模型中的CCK8试剂盒检测HT-29细胞活性，*表示P小于0.05，与对照组比较；
图9为小分子多肽和SOCS1分子全长采用流式细胞术检测HT-29及凋亡情况；
图10为小分子多肽在其他凋亡相关慢性炎症疾病中对细胞凋亡的作用。
具体实施方式
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。
下列实施例中未注明具体条件的实验方法，通常按照常规条件或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。除非另行定义，文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明中。文中所述的较佳实施方法与材料仅作示范之用。
实施例1：小分子多肽的制备
小分子多肽的氨基酸序列如SEQ ID NO.1所示，小分子多肽合成在ABI 431A型固相多肽合成仪(美国PE公司)上进行。方法采用标准芴甲氧羰基(Fmoc)方案，精氨酸采用两次偶联。起始选用0.125mmol对羟甲基苯氧甲基聚苯乙烯树脂(HMP树脂)，按照多肽序列使肽链从羧基端逐个向氨基端延伸，每种氨基酸的用量为0.5mmol，与树脂的摩尔比为4∶1.各种氨基酸的α-氨基酸为Fmoc保护，其余侧链保护基团为：Ser(tBu)、Glu(OtBu)、Arg(Pmc)。第一个氨基酸连接到树脂上用4-二甲基吡啶，氨基酸活化用1-羟基苯并三唑和二环乙基碳，偶联后用体积分数为20％的
哌啶水溶液去除Fmoc保护基。多肽粗品合成后，将树脂-粗肽在冰冷浴条件下混合于10ml切割液A(由结晶苯酚0.75g、1，2-乙二硫醇0.25ml、苯甲硫醚0.5ml、去离子水0.25ml和三氟乙酸10ml组成)中，待切割液温度上升至室温后，搅拌2小时，使肽链从树脂上裂解下来，同时去除多种保护基团，将反应混合液经G4玻砂漏斗过滤后以除去树脂，先后用1ml三氟乙酸，10ml二氯甲烷反复冲洗反应瓶，树脂和漏斗。将滤液在常温低压下蒸发至1-2ml，加入50ml预冷乙醚蒸发小分子多肽粗品，-20°保存备用。
将小分子多肽粗品用二甲基亚砜溶解成浓度为20mg/ml的溶液，经孔径为0.45um的绿孔滤膜过滤后，在AKTA explorer 100型中压液相色谱仪(瑞典amerssam bioscience)上用SOURCE凝胶柱上纯化。流动相A有体积百分比为10％的乙醇和体积百分含量为0.1％三氟乙酸组成，流动相B由体积百分含量为90％的乙醇和体积百分含量为0.1％三氟乙酸组成。先用流动相A 1.5个柱体积洗脱，再用流动相A和流动相B的混合液。(流动相B占混合液的体积分数在8个柱体积内由0％逐渐增加至80％)洗脱，再用流动相A和流动相B的混合液(流动相B占混合液的体积分数在0.5个柱体积内由0％逐渐增加至80％)洗脱，在主峰处收集多肽溶液，冷却干燥，即得小分子多肽纯品，用二甲基亚砜溶解，-20°保存备用。
将小分子多肽纯品用Delta 600型高压液相色谱仪(美国waters公司)鉴定纯度，采用symmetry shield C18柱，流动相由体积百分含量为10％到60％的乙和体积百分含量为0.1％的三氟乙酸组成，梯度洗脱，流速为1ml/min。结果显示，合成多肽的纯度达到90％以上。同时，将小分子多肽纯品用API2000LC/MS型电喷雾离子化质谱仪测定分子量。结果显示，合成的小分子多肽的分子量与理论值相符。
实施例2小分子多肽在治疗小鼠克罗恩病中的应用
1、动物：
雌性BalB/C小鼠，体重13-14克，购于南通大学动物实验室，正常饲养于清洁动物房。2、药物：
小分子多肽治疗组：给予如SEQ ID NO：1所示的小分子多肽20nmol/kg体重进行腹腔注射，共计6只；
空白组：给予与治疗组等体积的PBS进行腹腔注射，共计6只。
3、实验方法：
结肠灌注TNBS是克罗恩病常用动物建模方法，本实验用于验证多肽小分子对克罗恩病的治疗作用。结肠灌注TNBS方法，具体为：
1)成年健康的13-14g BALB/C雌鼠，禁食24小时，腹腔注射全身麻醉；
2)给予上述小鼠进行戊巴比妥钠腹腔麻醉；
3)将TNBS于无水乙醇1:2混合，取0.10ml用导管插入肛门内4cm注入，在导入药液的时候采取头低尾高的体位,防止灌注液体外溢；
4)轻轻去除导管，将小鼠倒提60s，使药液达到全结肠；
5)造模后小鼠平躺,自然清醒,常规饲养。
手术后立即经腹腔分别给空白组小鼠注射PBS，小分子多肽组小鼠注射小分子多肽，随后每24小时注射一次，共注射7次。
疾病活动指数(DAI)的检测：
每天观察小鼠的粪便性状、进食情况和精神状态,并记录体重、粪便性状和便血情况。进行小鼠DAI(疾病活动指数)评分。克罗恩小鼠DA1评分标准如表1所示：
表1小鼠TNBS结肠炎DAI评分标准
【DAI＝(体重下降分数+大便性状分数+便血分数)/3】
克罗恩小鼠DA1评分结果如图1所示，可见经SEQ ID NO：1所示的小分子多肽治疗的克罗恩小鼠DA1评分明显低于PBS对照治疗的克罗恩小鼠，表明如SEQ IDNO：1所示的小分子多肽均能显著改善克罗恩小鼠的粪便性状、进食情况和精神状态，具有治疗保护作用(*表示P小于0.05，与空白组比较)。
大体观察及评分：
小鼠处死后，75％酒精浸泡，固定于鼠板之上。沿腹中线逐层剪开皮肤、皮下组织、腹膜，钝性分离肠系膜及脂肪组织，自回盲部剪断。测量小鼠自回盲部至直肠的结肠长度，与对照小鼠比较。沿肠壁长轴纵向剪开结肠、直肠，在高压灭菌PBS液中充分洗涤，肉眼观察肠粘膜有无损伤、充血水肿及溃疡，对结肠进行大体评分。克罗恩小鼠大体评分标准如表2所示：
表2小鼠TNBS结肠炎大体评分标准
克罗恩小鼠大体评分结果如图2所示，可见经SEQ ID NO：1所示的小分子多肽治疗的克罗恩小鼠大体评分明显低于PBS对照治疗的克罗恩小鼠，表明如SEQ IDNO：1所示的小分子多肽均能显著改善克罗恩肠粘膜有损伤、充血水肿及溃疡，具有治疗保护作用(*表示P小于0.05，与空白组比较)。
组织学评分：
为了考察损伤肠道粘膜组织损伤情况，取结肠组织中病变最明显的部位，进行病理切片制作,HE染色，观察结肠白细胞浸润程度、杯状细胞形态、血管密度及肠壁厚度，进行组织学评分。克罗恩小鼠大体评分标准如表3所示：
表3小鼠TNBS结肠炎组织学评分标准
克罗恩小鼠组织学评分结果如图3所示，可见经SEQ ID NO：1所示的小分子多肽治疗的克罗恩小鼠组织学评分明显低于PBS对照治疗克罗恩小鼠，表明如SEQ IDNO：1所示的小分子多肽均能显著改善克罗恩炎性细胞浸润，具有治疗保护作用(*表示P小于0.05，与对照组比较)。
实施例3 SOCS1和FYN的相互作用
1、细胞：HT-29细胞，购买于上海奥陆生物公司，所用培养基为1640完培。使用时用加入终浓度为10％的胎牛血清，并且每毫升加入100单位青霉素和100ug链霉素。于37℃、5％CO2、湿润空气的细胞培养箱中进行培养。培养基每两天更换一次，每4-5天进行传代。传代时用EDTA消化液(PBS/EDTA：2g乙二胺四乙酸二钠(EDTA-Na2)加至1000mlPBS中，NaOH调节pH值至7.8，直至EDTA-Na2完全溶解，高压灭菌后4℃保存)消化细胞至大部分贴壁细胞脱落后终止消化，吹打离心后取适量细胞传入新的培养瓶。
2.材料方法：
1)H2O2刺激HT-29细胞，用EDTA/PBS缓冲液消化收集至少1×107细胞，PBS洗涤2次，加入1ml预冷RIPA裂解液，充分混匀，在冰上静置裂解10分钟。
2)轮转仪中4℃轮转2小时。
3)再次将细胞裂解混合液在冰上静置5分钟，4℃离心机中12000rpm离心10分钟，取上清蛋白液用于后续实验，BCA法检测蛋白浓度，取30μg做为input备用。
4)取300μg蛋白样品，加入SOCS1单克隆抗体(rabbit；1:50,Santa Cruz,USA)，于旋转器上缓慢旋转混匀，4℃冰箱中过夜。
5)第二天蛋白抗体混合液中加入30μL磁珠，4℃旋转器上混匀孵育3小时。
6)随后在磁珠分离仪上用PBS小心洗涤磁珠3次，用RIPA裂解液重悬磁珠，并加入LDS上样缓冲液，于70℃加热10分钟。
7)上清蛋白用10％Bis-Tris胶分离，Western Blot检测SOCS1和FYN表达。用同样方法在4步骤中加入FYN单克隆抗体(mouse；1:50,Santa Cruz,USA)，最后Western Blot检测SOCS1和FYN的表达。
3.结果如图4所示SOCS1和FYN存在明显的相互作用。
实施例4 SOCS1和FYN相互作用的结构域
1、细胞：293T细胞，购买于中国科学院细胞库，所用培养基为DMEM完培。使用时用加入终浓度为10％的胎牛血清，并且每毫升加入100单位青霉素和100ug链霉素。于37℃、5％CO2、湿润空气的细胞培养箱中进行培养。培养基每两天更换一次，每4-5天进行传代。传代时用PBS吹打离心后取适量细胞传入新的培养瓶。
2.材料方法：
1)HA-FYN分别和GFP-SOCS1、GFP-SOCS1S1、GFP-SS2、GFP-SOCS1S3共转染293T细胞24h；EDTA/PBS缓冲液消化收集293T细胞，至少1×107细胞，PBS洗涤2次，加入1ml预冷RIPA裂解液，充分混匀，在冰上静置裂解10分钟。其中，SOCS1S1、SS2、SOCS1S3分别是SOCS1的不同截短多肽，SOCS1具有如SEQ ID No：3所示的氨基酸序列，SOCS1S1具有如SEQ ID No：4所示的氨基酸序列，SS2具有如SEQ ID No：1所示的氨基酸序列，SOCS1S3具有如SEQ ID No：5所示的氨基酸序列。
2)轮转仪中4℃轮转2小时。
3)再次将细胞裂解混合液在冰上静置5分钟，4℃离心机中12000rpm离心10分钟，取上清蛋白液用于后续实验，BCA法检测蛋白浓度，取30μg做为input备用。
4)取300μg蛋白样品，加入GFP单克隆抗体(rabbit；1:50,Santa Cruz,USA)，于旋转器上缓慢旋转混匀，4℃冰箱中过夜。
5)第二天蛋白抗体混合液中加入30μL磁珠，4℃旋转器上混匀孵育3小时。
6)随后在磁珠分离仪上用PBS小心洗涤磁珠3次，用RIPA裂解液重悬磁珠，并加入LDS上样缓冲液，于70℃加热10分钟。
7)上清蛋白用10％Bis-Tris胶分离，Western Blot检测HA。
3.结果如图5所示SOCS1的SS2结构域和FYN存在明显的相互作用。
实施例5小分子多肽在细胞模型中的功能试验
1.细胞：HT-29细胞，购买于上海奥陆生物公司，所用培养基为1640完培。使用时用加入终浓度为10％的胎牛血清，并且每毫升加入100单位青霉素和100ug链霉素。于37℃、5％CO2、湿润空气的细胞培养箱中进行培养。培养基每两天更换一次，每4-5天进行传代。传代时用EDTA消化液(PBS/EDTA：2g乙二胺四乙酸二钠(EDTA-Na2)加至1000mlPBS中，NaOH调节p H值至7.8，直至EDTA-Na2完全溶解，高压灭菌后4℃保存)消化细胞至大部分贴壁细胞脱落后终止消化，吹打离心后取适量细胞传入新的培养瓶
2.材料方法：H2O2刺激HT-29细胞是克罗恩病常用细胞建模方法，本实验用于验证多肽小分子对克罗恩病的治疗作用。采用H2O2进行刺激，同时使用GFP-SS2、GFP-SOCS1S1、GFP-SOCS1S3转染刺激细胞72h。以H2O2刺激同时GFP-SS2转染为实验组，H2O2刺激同时无转染、H2O2刺激同时GFP-SOCS1S1、GFP-SOCS1S3转染为对照组，control是指未处理细胞作为空白组。
①流式细胞术检测HT-29及凋亡情况。胰酶消化转染刺激后HT-29细胞，3min后加入完培终止消化。PBS洗涤细胞后将单细胞悬浮液放于3mmol/L Newport Green以及0.2nmol/L Tetramethylrhodamine ethyl ester(TMRE)37℃条件下孵育45min，洗涤之后加入1g/L PI 4℃孵育15min。将细胞悬浮液用流式细胞仪(Beckerman FC500)分析。
结果如图6所示，与对照组、空白组相比，实验组SS2转染抑制细胞凋亡。
②FACS检测细胞周期，细胞转染72h后收集细胞，以75％乙醇固定，－20℃保存24h后，以1000r·min－1离心5min，弃上清，加入3ml PBS，弹松细胞，静置15min，离心后弃上清。加入500μl×binding buffer重悬细胞。细胞悬液中加入5μl AnnexinⅤ-FITC试剂，混匀后4℃避光孵育15min，加入10μl PI，轻轻混匀，4℃避光孵育5min，1h内送检。
结果如图7所示，与对照组、空白组相比，实验组SS2转染抑制细胞凋亡。
③CCK8试剂盒检测HT-29细胞活性接种于96孔板的转染刺激后的HT-29细胞,加入CCK8试剂10l/孔(每组均设置6个复孔),置于CO2细胞培养箱37℃、5％CO2条件下孵4h后,在酶联免疫检测仪上测450nm的吸光度(A)值；计算细胞相对活力:细胞相对活力＝(实验组(A)平均值/对照组(A)平均值)
结果如图8所示(*p<0.05,与对照组比较)，与对照组、空白组相比，SS2转染抑制细胞凋亡。
3.综上，SS2序列高表达抑制H2O2刺激下的细胞凋亡，而SOCS1的其他截短序列S1、S3则没有这一作用。
实施例6小分子多肽和SOCS1分子全长在细胞中发挥功能的比较
1.细胞：HT-29细胞，购买于上海奥陆生物公司，所用培养基为1640完培。使用时用加入终浓度为10％的胎牛血清，并且每毫升加入100单位青霉素和100ug链霉素。于37℃、5％CO2、湿润空气的细胞培养箱中进行培养。培养基每两天更换一次，每4-5天进行传代。传代时用EDTA消化液(PBS/EDTA：2g乙二胺四乙酸二钠(EDTA-Na2)加至1000mlPBS中，Na OH调节p H值至7.8，直至EDTA-Na2完全溶解，高压灭菌后4℃保存)消化细胞至大部分贴壁细胞脱落后终止消化，吹打离心后取适量细胞传入新的培养瓶。
2.材料方法：本实验用于比较多肽小分子与SOCS1对克罗恩病的治疗作用。采用H2O2进行刺激，同时使用GFP-SS2、GFP-SOCS1转染刺激细胞72h。流式细胞术检测HT-29及凋亡情况。胰酶消化转染刺激后HT-29细胞，3min后加入完培终止消化。PBS洗涤细胞后将单细胞悬浮液放于3mmol/L Newport Green以及0.2nmol/L Tetramethylrhodamineethylester(TMRE)37℃条件下孵育45min，洗涤之后加入1g/L PI 4℃孵育。
3.结果如图9所示(*p<0.05,与对照组比较)，SS2序列相比于GFP-SOCS1对细胞凋亡的抑制作用更为明显。
实施例7小分子多肽在其他凋亡相关慢性炎症疾病中对细胞凋亡的作用
1.细胞：SW1353人软骨肉瘤细胞(Institute of Biochemistry andell Biology,Shanghai,China)，所用培养基为DMEM完培。使用时用加入终浓度为10％的胎牛血清，并且每毫升加入100单位青霉素和100ug链霉素。于37℃、5％CO2、湿润空气的细胞培养箱中进行培养。培养基每两天更换一次，每4-5天进行传代。
2.材料方法：人类骨关节炎与克罗恩病都属凋亡相关的慢性炎症疾病，IL-1β刺激SW1353是骨关节炎的常用细胞建模手段，IL-1β刺激可以导致SW1353细胞发生显著的凋亡。本实验使用10ng/ml IL-1β(SigmaAldrich)刺激细胞，并使用GFP-SOCS1、GFP-SOCS1S1、GFP-SS2、GFP-SOCS1S3转染细胞72小时，后用流式细胞术检测细胞凋亡情况。(具体方法同上)
3.结果如图10所示(*p<0.05,与对照组比较)，SS2小分子多肽对IL-1β诱导的SW1353凋亡同样具有抑制作用，SS2在多种凋亡相关疾病中都可能发挥抑制疾病进展的作用。
以上已对本发明创造的较佳实施例进行了具体说明，但本发明创造并不限于所述实施例，熟悉本领域的技术人员在不违背本发明创造精神的前提下还可作出种种的等同的变型或替换，这些等同的变型或替换均包含在本申请权利要求所限定的范围内。
SEQUENCE LISTING
<110> 南通大学
<120> 一种小分子多肽、及其编码基因和应用
<130> 权利要求书、说明书
<160> 5
<170> PatentIn version 3.3
<210> 1
<211> 71
<212> PRT
<213> 人工序列
<400> 1
Gly Phe Tyr Trp Gly Pro Leu Ser Val His Gly Ala His Glu Arg Leu
1 5 10 15
Arg Ala Glu Pro Val Gly Thr Phe Leu Val Arg Asp Ser Arg Gln Arg
20 25 30
Asn Cys Phe Phe Ala Leu Ser Val Lys Met Ala Ser Gly Pro Thr Ser
35 40 45
Ile Arg Val His Phe Gln Ala Gly Arg Phe His Leu Asp Gly Ser Arg
50 55 60
Glu Ser Phe Asp Cys Leu Phe
65 70
<210> 2
<211> 206
<212> DNA
<213> 人工序列
<400> 2
actgggggcc cctgagcgtg cacggggcgc acgagcggct gcgcgccgag cccgtgggca 60
ccttcctggt gcgcgacagc cgccagcgga actgcttttt cgcccttagc gtgaagatgg 120
cctcgggacc cacgagcatc cgcgtgcact ttcaggccgg ccgctttcac ctggatggca 180
gccgcgagag cttcgactgc ctcttc 206
<210> 3
<211> 211
<212> PRT
<213> 人工序列
<400> 3
Met Val Ala His Asn Gln Val Ala Ala Asp Asn Ala Val Ser Thr Ala
1 5 10 15
Ala Glu Pro Arg Arg Arg Pro Glu Pro Ser Ser Ser Ser Ser Ser Ser
20 25 30
Pro Ala Ala Pro Ala Arg Pro Arg Pro Cys Pro Ala Val Pro Ala Pro
35 40 45
Ala Pro Gly Asp Thr His Phe Arg Thr Phe Arg Ser His Ala Asp Tyr
50 55 60
Arg Arg Ile Thr Arg Ala Ser Ala Leu Leu Asp Ala Cys Gly Phe Tyr
65 70 75 80
Trp Gly Pro Leu Ser Val His Gly Ala His Glu Arg Leu Arg Ala Glu
85 90 95
Pro Val Gly Thr Phe Leu Val Arg Asp Ser Arg Gln Arg Asn Cys Phe
100 105 110
Phe Ala Leu Ser Val Lys Met Ala Ser Gly Pro Thr Ser Ile Arg Val
115 120 125
His Phe Gln Ala Gly Arg Phe His Leu Asp Gly Ser Arg Glu Ser Phe
130 135 140
Asp Cys Leu Phe Glu Leu Leu Glu His Tyr Val Ala Ala Pro Arg Arg
145 150 155 160
Met Leu Gly Ala Pro Leu Arg Gln Arg Arg Val Arg Pro Leu Gln Glu
165 170 175
Leu Cys Arg Gln Arg Ile Val Ala Thr Val Gly Arg Glu Asn Leu Ala
180 185 190
Arg Ile Pro Leu Asn Pro Val Leu Arg Asp Tyr Leu Ser Ser Phe Pro
195 200 205
Phe Gln Ile
210
<210> 4
<211> 77
<212> PRT
<213> 人工序列
<400> 4
Met Val Ala His Asn Gln Val Ala Ala Asp Asn Ala Val Ser Thr Ala
1 5 10 15
Ala Glu Pro Arg Arg Arg Pro Glu Pro Ser Ser Ser Ser Ser Ser Ser
20 25 30
Pro Ala Ala Pro Ala Arg Pro Arg Pro Cys Pro Ala Val Pro Ala Pro
35 40 45
Ala Pro Gly Asp Thr His Phe Arg Thr Phe Arg Ser His Ala Asp Tyr
50 55 60
Arg Arg Ile Thr Arg Ala Ser Ala Leu Leu Asp Ala Cys
65 70 75
<210> 5
<211> 63
<212> PRT
<213> 人工序列
<400> 5
Glu Leu Leu Glu His Tyr Val Ala Ala Pro Arg Arg Met Leu Gly Ala
1 5 10 15
Pro Leu Arg Gln Arg Arg Val Arg Pro Leu Gln Glu Leu Cys Arg Gln
20 25 30
Arg Ile Val Ala Thr Val Gly Arg Glu Asn Leu Ala Arg Ile Pro Leu
35 40 45
Asn Pro Val Leu Arg Asp Tyr Leu Ser Ser Phe Pro Phe Gln Ile
50 55 60
Claims (8)
1.一种小分子多肽，其氨基酸序列如SEQ ID NO.1所示。
2.一种编码权利要求1所述的小分子多肽的基因，其核苷酸序列如SEQ ID NO.2所示。
3.根据权利要求1所述的小分子多肽在制备治疗慢性炎症疾病药物中的应用，所述的慢性炎症疾病是指肠上皮细胞在炎症环境下，由细胞因子激活产生的SOCS1被氧化应激诱导产生Fyn磷酸化，使SOCS1失去抑制细胞凋亡能力的疾病。
4.根据权利要求3所述的小分子多肽在制备治疗慢性炎症疾病药物中的应用，其特征在于：所述的慢性炎症疾病为克罗恩病。
5.根据权利要求2所述的基因在制备治疗慢性炎症疾病药物中的应用，所述的慢性炎症疾病是指肠上皮细胞在炎症环境下，由细胞因子激活产生的SOCS1被氧化应激诱导产生Fyn磷酸化，使SOCS1失去抑制细胞凋亡能力的疾病。
6.根据权利要求5所述的基因在制备治疗慢性炎症疾病药物中的应用，其特征在于：所述的慢性炎症疾病为克罗恩病。
7.一种药物组合物，其特征在于，其包含如权利要求1所述的小分子多肽以及药学上可接受的载体。
8.根据权利要求7所述的药物组合物，其特征在于，所述药学上可接受的载体为药学上可接受的赋形剂、悬浮剂、填充剂和/或稀释剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610938432.6A CN106349347B (zh) | 2016-10-25 | 2016-10-25 | 一种小分子多肽、及其编码基因和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610938432.6A CN106349347B (zh) | 2016-10-25 | 2016-10-25 | 一种小分子多肽、及其编码基因和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106349347A CN106349347A (zh) | 2017-01-25 |
| CN106349347B true CN106349347B (zh) | 2019-09-13 |
Family
ID=57864119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610938432.6A Active CN106349347B (zh) | 2016-10-25 | 2016-10-25 | 一种小分子多肽、及其编码基因和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106349347B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103397103A (zh) * | 2013-08-26 | 2013-11-20 | 中国人民解放军第三军医大学第三附属医院 | 一种检测socs家族基因标签单核甘酸多态性位点的方法及试剂盒 |
| WO2015112904A1 (en) * | 2014-01-24 | 2015-07-30 | University Of Florida Research Foundation, Inc. | Socs mimetics for the treatment of diseases |
| WO2015181427A1 (es) * | 2014-05-28 | 2015-12-03 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030175971A1 (en) * | 2001-12-28 | 2003-09-18 | Geoffrey Lindeman | Differentiation and/or proliferation modulating agents and uses therefor |
-
2016
- 2016-10-25 CN CN201610938432.6A patent/CN106349347B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103397103A (zh) * | 2013-08-26 | 2013-11-20 | 中国人民解放军第三军医大学第三附属医院 | 一种检测socs家族基因标签单核甘酸多态性位点的方法及试剂盒 |
| WO2015112904A1 (en) * | 2014-01-24 | 2015-07-30 | University Of Florida Research Foundation, Inc. | Socs mimetics for the treatment of diseases |
| WO2015181427A1 (es) * | 2014-05-28 | 2015-12-03 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Péptido derivado de socs1 para su uso en complicaciones crónicas de la diabetes |
Non-Patent Citations (6)
| Title |
|---|
| A three-dimensional model of Suppressor Of Cytokine Signalling 1(SOCS-1);Fabrizio Giordanetto 等;《Protein Engineering》;20030201;第16卷(第2期);第115-124页 * |
| On-Bead Screening of Combinatorial Libraries: Reduction of Nonspecific Binding by Decreasing Surface Ligand Density;Xianwen Chen 等;《J Comb Chem.》;20090731;第11卷(第4期);第604-611页 * |
| SOCS1与肿瘤发生、发展和治疗的研究进展;赵晓彪 等;《现代生物医学进展》;20150531;第2965-2968页 * |
| STAT蛋白在炎症性肠病发病机制中的作用;牛宏垚 等;《国际消化病杂志》;20070630;第27卷(第3期);第184页第4.1节 * |
| Structural and functional analysis of a nuclear localization signal in SOCS1;Christian Koelsche 等;《Molecular Immunology》;20091231;第46卷;第2474-2480页 * |
| 一种新的疾病治疗候选基因：SOCS-1;崔强 等;《生命科学》;20060630;第18卷(第3期);摘要，第291页左栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106349347A (zh) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | Emodin attenuates lipopolysaccharide-induced acute liver injury via inhibiting the TLR4 signaling pathway in vitro and in vivo | |
| CN102321158B (zh) | 阻止细胞dna合成抑制细胞增殖的多肽及用途 | |
| WO2011134271A1 (zh) | 苦柯胺a和苦柯胺b的用途 | |
| Gao et al. | Suppression of macrophage migration by down-regulating Src/FAK/P130Cas activation contributed to the anti-inflammatory activity of sinomenine | |
| Li et al. | Effect of curcumin on p38MAPK expression in DSS-induced murine ulcerative colitis | |
| Ao et al. | Matrine inhibits synovial angiogenesis in collagen-induced arthritis rats by regulating HIF-VEGF-Ang and inhibiting the PI3K/Akt signaling pathway | |
| CN111562394B (zh) | 热休克因子2结合蛋白在肝脏缺血再灌注损伤、药物性肝损伤中的应用 | |
| Han et al. | Irisin inhibits neutrophil extracellular traps formation and protects against acute pancreatitis in mice | |
| CN110157686B (zh) | 一种免疫检查点激活免疫共刺激的复制型溶瘤腺病毒及其构建方法和应用 | |
| Liu et al. | Chemotherapy‐induced phlebitis via the GBP5/NLRP3 inflammasome axis and the therapeutic effect of aescin | |
| Xiao et al. | Flavokawain A suppresses the vasculogenic mimicry of HCC by inhibiting CXCL12 mediated EMT | |
| WO2022143938A1 (zh) | 一种激活nk细胞的肿瘤免疫治疗方法 | |
| Zhao et al. | Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling | |
| CN106349347B (zh) | 一种小分子多肽、及其编码基因和应用 | |
| CN114668843B (zh) | 一种纳米自组装糖肽biva-pk及其在缺血再灌注损伤导致的肾脏纤维化中的应用 | |
| CN111743883A (zh) | 二苯甲酮衍生物组合物及其制备方法和用途 | |
| CN111035752B (zh) | 家蚕抗菌肽Cecropin A在食道癌治疗中的用途 | |
| CN106620651A (zh) | 热休克蛋白gp96在治疗溃疡性结肠炎中的应用 | |
| CN106924714B (zh) | 多肽c2orf40mpf在制备抗肿瘤药物中的应用 | |
| CN111534502A (zh) | 一种抗癌活性蛋白妙沙林及其编码基因和应用 | |
| CN101481412B (zh) | 一种具有抗肿瘤作用的多肽及其编码基因与应用 | |
| WO2016112787A1 (zh) | 天麻素或天麻粉在制备抗肝纤维化药物中的应用 | |
| CN103992394A (zh) | 一种人工合成的阳离子肽及其在制备抗肿瘤药物中的用途 | |
| CN104926943B (zh) | 凋亡素组合肽及其在制备抗肿瘤药物中的应用 | |
| JP2009276245A (ja) | 持続性皮膚炎症性疾患の改善剤をスクリーニングする方法及びその改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220329 Address after: 226006 Room 301, building 4, No. 109, Yongfu Road, Tangzha Town Street, Chongchuan District, Nantong City, Jiangsu Province Patentee after: Jiangsu Guochen Medical Technology Co.,Ltd. Address before: 226019 Jiangsu city of Nantong province sik Road No. 9 Patentee before: NANTONG University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240108 Address after: Room 301, No. 2 and 6, Lane 80, Yunxin Road, Jing'an District, Shanghai, 200040 Patentee after: SHANGHAI GENOMEPILOT TECHNOLOGY, Inc. Address before: 226006 Room 301, building 4, No. 109, Yongfu Road, Tangzha Town Street, Chongchuan District, Nantong City, Jiangsu Province Patentee before: Jiangsu Guochen Medical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |